Rivaroxaban or Aspirin for Patent Foramen Ovale and E
Source: A Prespecified Subgroup Analysis From the NAV

Lancet Neurology, The

17, 1053-1060

DOI: 10.1016/s1474-4422(18)30319-3

Citation Report

#	Article	IF	Citations
1	Embolic Stroke of Undetermined Source and Patent Foramen Ovale Closure: Practice Insights From Meta-Analysis?. Catheterization and Cardiovascular Interventions, 2018, 92, 1161-1162.	2.2	2
2	Optimal Stroke Prevention in Patients With Patent Foramen Ovale. Lancet Neurology, The, 2018, 17, 1027-1028.	43.7	7
3	Nach embolischem Schlaganfall: Antikoagulation bei PFO mit fraglichem Nutzen. CardioVasc, 2019, 19, 58-59.	0.0	0
4	Is Embolic Stroke of Undetermined Source Shrinking?. Stroke, 2019, 50, 2290-2291.	9.1	3
5	Recurrence Risk in Patients With Cryptogenic Stroke, Patent Foramen Ovale, and Thrombophilia: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2019, 119, 1839-1848.	4.6	24
6	Transcatheter Closure of Patent Foramen Ovale to Prevent Stroke Recurrence in Patients With Otherwise Unexplained Ischaemic Stroke: Expert Consensus of the French Neurovascular Society and the French Society of Cardiology. Archives of Cardiovascular Diseases, 2019, 112, 532-542.	2.5	32
7	Management of Patients With Patent Foramen Ovale and Cryptogenic Stroke: An Update. Cardiology, 2019, 143, 62-72.	1.7	38
8	Histological Examination of Thrombi in Patients With Cerebral Infarction in Embolic Stroke of Undetermined Source. Journal of Neuroendovascular Therapy, 2019, 13, 359-366.	1.2	2
9	Secondary Prevention of Ischaemic Stroke. Internal Medicine Journal, 2019, 49, 1221-1228.	1.6	1
10	Verschluss des persistierenden Foramen ovale nach ischämischem Schlaganfall. Deutsche Medizinische Wochenschrift, 2019, 144, 1561-1569.	0.3	4
11	Latin American Consensus Statement for the Use of Contrast-Enhanced Transcranial Ultrasound as a Diagnostic Test for Detection of Right-to-Left Shunt. Cerebrovascular Diseases, 2019, 48, 99-108.	2.1	21
12	Patent Foramen Ovale and Cryptogenic Stroke: Down the Hole!. Cardiology, 2019, 143, 73-76.	1.7	0
13	A Case-Based Discussion on the Management of Cryptogenic Stroke and Patent Foramen Ovale in the Patient With a Hypercoagulable Disorder. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 3476-3485.	2.1	1
14	Update antithrombotische Sekundärprophylaxe des ischämischen Schlaganfalls. Der Nervenarzt, 2019, 90, 995-1004.	1.3	0
15	Antithrombotic Treatment in Cryptogenic Stroke Patients With Patent Foramen Ovale. Stroke, 2019, 50, 3135-3140.	9.1	22
16	Patent Foramen Ovale: Story Closed?. Journal of Stroke, 2019, 21, 23-30.	7.6	11
17	Predictors of Recurrent Ischemic Stroke in Patients With Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 2273-2279.	2.2	30
18	Continuous 4-Week ECG Monitoring With Adhesive Electrodes Reveals AF in Patients With Recent Embolic Stroke of Undetermined Source. Annals of Noninvasive Electrocardiology, 2019, 24, e12649.	0.9	16

#	Article	IF	Citations
19	Embolischer Schlaganfall Unbekannter Quelle (ESUS). Klinikarzt, 2019, 48, 78-81.	0.0	0
20	Large Aortic Arch Plaques Correlate With CHADS2 and CHA2DS2-VASc Scores in Cryptogenic Stroke. Atherosclerosis, 2019, 284, 181-186.	7.0	34
21	Tailoring the Approach to Embolic Stroke of Undetermined Source: A Review. JAMA Neurology, 2019, 76, 855-861.	22.0	123
22	8. Jahrestagung der Vereinigung der interdisziplinären Gefäßmediziner Süddeutschlands (VIGS). Gefasschirurgie, 2019, 24, 176-181.	0.4	0
23	Closure of Patent Foramen Ovale and “Cryptogenic” Stroke: What's New, What's Next?. Archives of Cardiovascular Diseases, 2019, 112, 145-149.	2.5	3
24	Optimal Stroke Prevention in Patients With PFO. Lancet Neurology, The, 2019, 18, 231.	43.7	1
25	Role of PFO Closure in Ischemic Stroke Prevention. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 1-17.	1.3	6
26	Transcatheter Closure of Patent Foramen Ovale: Randomized Trial Update. Interventional Cardiology Clinics, 2019, 8, 341-356.	1.1	4
27	Anticoagulation in Patients With Embolic Stroke of Unknown Source. International Journal of Stroke, 2019, 14, 334-336.	7.4	10
28	Age-Related Burden and Characteristics of Embolic Stroke of Undetermined Source in the Real World Clinical Practice. Journal of Thrombosis and Thrombolysis, 2020, 49, 75-85.	2.2	12
29	Potential Role of 2-Phase Cardiac CT in Patients With Embolic Stroke of Undetermined Source. American Journal of Medicine, 2020, 133, e290-e293.	3.2	7
30	Patent Foramen Ovale and Stroke: Current Evidence and Treatment Options. Current Opinion in Neurology, 2020, 33, 10.	5.0	13
31	Reprint Of : Transcatheter Closure of Patent Foramen Ovale to Prevent Stroke Recurrence in Patients With Otherwise Unexplained Ischaemic Stroke: Expert Consensus of the French Neurovascular Society and the French Society of Cardiology. Revue Neurologique, 2020, 176, 53-61.	2.5	7
32	Patent Foramen Ovale in Patients With Atrial Fibrillation. International Journal of Cardiology, 2020, 300, 168-169.	3.2	1
33	Prevalence of Non-Stenotic (<50%) Carotid Plaques in Acute Ischemic Stroke and Transient Ischemic Attack: A Systematic Review and Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105117.	2.2	28
34	Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial. JAMA Neurology, 2020, 77, 1233-1240.	22.0	60
35	Prevalence of Patent Foramen Ovale in the Greek Population Is High and Impacts on the Interpretation of the Risk of Paradoxical Embolism (RoPE) Score. Therapeutic Advances in Neurological Disorders, 2020, 13, 1756286420964673.	4.0	13
36	Anticoagulation and Risk of Stroke Recurrence in Patients With Embolic Stroke of Undetermined Source Having No Potential Source of Embolism. Cerebrovascular Diseases, 2020, 49, 601-608.	2.1	5

#	Article	IF	Citations
37	It's Time to Say Goodbye to the ESUS Construct. Frontiers in Neurology, 2020, 11, 544650.	3.5	26
38	Comparison of Antithrombotic Strategies in Patients With Cryptogenic Stroke and Patent Foramen Ovale: An Updated Meta-Analysis. Cardiovascular Drugs and Therapy, 2021, 35, 987-993.	4.1	13
39	Patterns of Infarction on MRI in Patients With Acute Ischemic Stroke and Cardio-Embolism: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2020, 11, 606521.	3.5	36
40	Prevalence of Ipsilateral Nonstenotic Carotid Plaques on Computed Tomography Angiography in Embolic Stroke of Undetermined Source. Stroke, 2020, 51, 1743-1749.	9.1	70
41	Clinical RoPE (cRoPE) Score Predicts Patent Foramen Ovale Detection Among Stroke Patients: A Multicenter Observational Study. Neurological Sciences, 2020, 41, 3227-3233.	2.4	9
42	Epidemiology of Patent Foramen Ovale in General Population and in Stroke Patients: A Narrative Review. Frontiers in Neurology, 2020, 11, 532863.	3.5	153
43	A Narrative and Critical Review of Randomized-Controlled Clinical Trials on Patent Foramen Ovale Closure for Reducing the Risk of Stroke Recurrence. Frontiers in Neurology, 2020, 11, 543976.	3.5	21
44	Der zweite Blick: praktische diagnostische und therapeutische Checks in der rehabilitativen Neurologie. Der Nervenarzt, 2020, 91, 324-336.	1.3	2
45	Embolic Stroke of Undetermined Source and Symptomatic Nonstenotic Carotid Disease. Stroke, 2020, 51, 1321-1325.	9.1	55
46	Clinical Features of Embolic Stroke of Undetermined Source. Frontiers in Neurology, 2020, 11, 509947.	3.5	8
47	Expert Consensus Statement for the Management of Patients With Embolic Stroke of Undetermined Source and Patent Foramen Ovale: A Clinical Guide by the Working Group for Stroke of the Hellenic Society of Cardiology and the Hellenic Stroke Organization. Hellenic Journal of Cardiology, 2020, 61, 435-441.	2.0	7
48	Prognosis of Cryptogenic Stroke With Patent Foramen Ovale at Older Ages and Implications for Trials: A Population-Based Study and Systematic Review. JAMA Neurology, 2020, 77, 1279-1287.	22.0	57
49	Updates in the Management of Cryptogenic Stroke and Patent Foramen Ovale. Journal of Neuro-Ophthalmology, 2020, 40, 60.	1.8	1
50	Causes and Secondary Prevention of Acute Ischemic Stroke in Adults. Hamostaseologie, 2020, 40, 022-030.	1.5	31
51	Examining the Evidence for PFO Closure and Novel Oral Anticoagulants for Treatment of Cryptogenic Stroke. Expert Review of Cardiovascular Therapy, 2020, 18, 139-148.	2.7	1
52	Meta-Analysis of Secondary Prevention of Cryptogenic Stroke. Cardiovascular Revascularization Medicine, 2020, 21, 1285-1290.	1.6	3
53	Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention. Neurology, 2020, 94, 876-885.	5.0	194
54	Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale–Associated Stroke. JAMA Neurology, 2020, 77, 878-886.	22.0	206

#	Article	IF	Citations
55	Vergangenheit und Zukunft des ESUS-Konzepts. Der Nervenarzt, 2020, 91, 511-517.	1.3	3
56	Embolic Stroke of Undetermined Source: Gateway to a New Stroke Entity?. American Journal of Medicine, 2020, 133, 795-801.	3.2	13
57	Aspirin or Anticoagulation After Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Neurological Sciences, 2020, 41, 2819-2824.	2.4	14
58	Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial. Stroke, 2020, 51, 1797-1804.	9.1	74
59	Diagnosis and Treatment for Embolic Stroke of Undetermined Source: Consensus Statement From the Taiwan Stroke Society and Taiwan Society of Cardiology. Journal of the Formosan Medical Association, 2021, 120, 93-106.	2.2	9
60	Embolic Stroke of Undetermined Source: The Need for an Integrated and Holistic Approach to Care. Thrombosis and Haemostasis, 2021, 121, 251-254.	4.6	4
61	Atrial Cardiopathy and Likely Pathogenic Patent Foramen Ovale in Embolic Stroke of Undetermined Source. Thrombosis and Haemostasis, 2021, 121, 361-365.	4.6	12
62	Posterior Circulation Stroke. , 2021, .		1
63	Treatment of Foramen Ovale With Stroke Patients: A Review. American Journal of Surgery and Clinical Case Reports, 2021, .	0.0	0
64	Кардиоэмболический инсульт при синдроме некомпактного миокарда. Russian Neurological Journal, 2021, 25, 29-34.	0.3	0
65	Atrial Fibrillation in Patients With Embolic Stroke of Undetermined Source During 3 Years of Prolonged Monitoring With an Implantable Loop Recorder. Thrombosis and Haemostasis, 2021, 121, 826-833.	4.6	44
66	Aortic Sources of Embolism. Frontiers in Neurology, 2021, 11, 606663.	3.5	25
67	1. Nosotchu, 2021, 43, 327-331.	0.2	0
68	Management of Patients With a Patent Foramen Ovale With History of Stroke or TIA. JAMA - Journal of the American Medical Association, 2021, 325, 81-82.	37.0	17
69	Patent Foramen Ovale Closure in the Management of Cryptogenic Stroke: A Review of Current Literature and Guideline Statements. Current Medical Research and Opinion, 2021, 37, 377-384.	2.9	27
70	Sex- Related Differences in the Factors Associated With Outcomes Among Patients With Strokes of Undetermined Source: A Hospital-Based Follow-Up Study. Postgraduate Medicine, 2021, 133, 428-435.	3.0	2
71	Neues Beim Schlaganfall – Teil 2: Prävention. Neurologie Up2date, 2021, 4, 51-66.	0.1	1
72	Ischemic Stroke and Heart Failure: Facts and Numbers. An Update. Journal of Clinical Medicine, 2021, 10, 1146.	3.8	34

#	Article	IF	Citations
73	Accidente Ischemico Cerebrale e Retinico Transitorio. EMC - Neurologia, 2021, 21, 1-15.	0.0	0
74	Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale. Stroke, 2021, 52, 1065-1068.	9.1	40
75	Embolischer Schlaganfall mit ungeklärter Emboliequelle (ESUS) – Klassifikation einer neuen Schlaganfallentität. Deutsche Medizinische Wochenschrift, 2021, 146, 403-409.	0.3	2
76	Comparing the Diagnostic Value of Echocardiography in Stroke (CEIS) – Results of a Prospective Observatory Cohort Study. BMC Neurology, 2021, 21, 1-7.	2.8	7
77	Shouldn't Patients With Paradoxical Emboli and Thrombophilia Be Given Anticoagulant Agents?. JACC: Cardiovascular Interventions, 2021, 14, 583.	5.0	0
78	The Prevalence of Microembolic Signals in Transcranial Doppler Sonography With Bubble Test in Acute Ischemic Stroke. Journal of Ultrasound in Medicine, 2022, 41, 439-446.	2.6	4
79	Closure or Medical Therapy of Patent Foramen Ovale in Cryptogenic Stroke: Prospective Case Series. Neurological Research and Practice, 2021, 3, 1-10.	3.3	18
80	Presence of Atrial Fibrillation in Stroke Patients With Patent Foramen Ovale: Systematic Review and Meta-Analysis. Frontiers in Neurology, 2021, 12, 613758.	3.5	5
81	Atrial Septal Aneurysm May Cause In-Hospital Recurrence of Cryptogenic Stroke. Journal of Atherosclerosis and Thrombosis, 2021, 28, 514-523.	3.7	7
82	Stroke Prevention: Little-Known and Neglected Aspects. Cerebrovascular Diseases, 2021, 50, 622-635.	2.1	13
83	Secondary Stroke Prevention in Patients With Patent Foramen Ovale. Current Opinion in Hematology, 2021, 28, 292.	3.2	3
84	2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke, 2021, 52, e364-e467.	9.1	3,042
85	Oral Anticoagulants vs Antiplatelets in Cryptogenic Stroke With Potential Cardiac Emboli: Meta-Analysis. European Journal of Internal Medicine, 2022, 95, 44-49.	4.2	8
86	Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial. Stroke, 2022, 53, 45-52.	9.1	16
87	Non-Stenotic Carotid Plaques in Embolic Stroke of Unknown Source. Frontiers in Neurology, 2021, 12, 719329.	3.5	37
88	Embolic Stroke of Undetermined Source: Identification of Patient Subgroups for Oral Anticoagulation Treatment. Neural Regeneration Research, 2022, 17, 1005.	5.9	6
89	Embolic Stroke of Undetermined SourceESUS. Nosotchu, 2022, 44, 119-126.	0.2	1
90	Endovascular Closure of Patent Foramen Ovale: A Critical Appraisal of Published Trials. Arquivos De Neuro-Psiquiatria, 2019, 77, 731-740.	0.6	5

#	Article	IF	Citations
91	Simultaneous Multifocal Paradoxical Embolism in an Elderly Patient With Patent Foramen Ovale: A Case Report. Cureus, 2020, 12, e6992.	1.3	6
92	Neues Beim Schlaganfall: Prävention. Geriatrie Up2date, 2021, 03, 291-306.	0.1	0
93	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. Circulation, 2021, 144, 1323-1343.	24.6	76
94	Treatment Strategies for Cryptogenic Stroke Patients With Patent Foramen Ovale: What Do We Choose?. Neuropsychiatric Disease and Treatment, 2021, 17, 3205-3214.	3.3	3
95	NAVIGATE ESUS re-SPECT ESUS . Japanese Journal of Thrombosis and Hemostasis, 2019, 30, 828-836.	0.1	0
96	Patent Foramen Ovale: Risk Factors and Diagnostic Comparison of Transcranial Doppler Versus Echocardiography for Secondary Stroke Prevention. Journal of Neurosonology and Neuroimaging, 2019, 11, 22-33.	0.4	4
97	Non Vitamin K Oral Anticoagulants Versus Antiplatelets in Embolic Stroke of Undetermined Source: Most Updated Evidence. Minerva Cardioangiologica, 2019, 67, 340-347.	1.1	1
98	Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism Beyond Atrial Fibrillation. Journal of Stroke, 2019, 21, 259-275.	7.6	7
99	Recent Advances in Preventing Recurrent Stroke. F1000Research, 2020, 9, 1012.	1.1	1
100	Embolic Stroke of Undetermined Source: Approaches in Risk Stratification for Cardioembolism. Stroke, 2021, 52, e820-e836.	9.1	23
101	Stroke Prevention in Patients With Patent Foramen Ovale. Current Cardiology Reports, 2021, 23, 1-7.	4.5	5
102	Uncertainties and Controversies in the Management of Ischemic Stroke and Transient Ischemic Attack Patients With Patent Foramen Ovale. Stroke, 2021, 52, e806-e819.	9.1	22
103	Stroke Prevention and Treatment: An Evidence-Based Approach. , 2020, .		12
104	Non-Vitamin K Oral Anticoagulants (NOACs) in Patients With Stroke and Atrial Fibrillation. Arhiv Za Farmaciju, 2020, 70, 269-283.	0.7	0
105	Patent Foramen Ovale Closure for Stroke, Myocardial Infarction, Peripheral Embolism, Migraine, and Hypoxemia. , 2020, .		5
106	Praxishandbuch Schlaganfall. , 2020, .		1
107	Evolving Approaches to Antithrombotics in Stroke Prevention and Treatment. Southern Medical Journal, 2020, 113, 585-592.	0.7	0
108	Medical Treatment. , 2021, .		0

#	Article	IF	Citations
109	Patent Foramen Ovale, the Role of Antiplatelet Therapy Alone or Anticoagulant Therapy Alone Versus Device Closure for Cryptogenic Stroke: A Review of the Literature and Current Recommendations. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2020, 18, 135-150.	1.5	2
110	Inpatient Management of Acute Stroke and Transient Ischemic Attack. Neurologic Clinics, 2022, 40, 33-43.	4.3	9
111	Advances in the Management of Cardioembolic Stroke Associated With Patent Foramen Ovale. BMJ, The, 2022, 376, e063161.	11.6	42
112	Dabigatran Versus Aspirin for Stroke Prevention After Cryptogenic Stroke With Patent Foramen Ovale: A Prospective Study. Clinical Neurology and Neurosurgery, 2022, 215, 107189.	1.9	11
113	Unique Clinicopathologic Subclassifiers of Cryptogenic Cerebral Emboli. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106427.	2.2	6
114	A Critical Assessment of the Current Pharmacotherapy for the Treatment of Embolic Strokes of Undetermined Source. Expert Opinion on Pharmacotherapy, 2022, 23, 905-915.	3.5	4
115	Current Challenges and Future Directions in Handling Stroke Patients With Patent Foramen Ovale—A Brief Review. Frontiers in Neurology, 2022, 13, 855656.	3.5	14
116	Review and Update of the Concept of Embolic Stroke of Undetermined Source. Nature Reviews Neurology, 2022, 18, 455-465.	35.8	109
117	Management of Patients With Embolic Stroke of Unknown Source: Interpreting the Evidence in the Light of Clinical Judgement. Current Neurology and Neuroscience Reports, 2022, 22, 389-393.	8.7	5
118	SCAI Technical Review on Management of Patent Foramen Ovale. Journal of the Society for Cardiovascular Angiography & Interventions, 2022, 1, 100040.	2.3	4
119	SCAI Guidelines for the Management of Patent Foramen Ovale. Journal of the Society for Cardiovascular Angiography & Interventions, 2022, 1, 100039.	2.3	176
120	Evaluating the Potential Pathology and Short-Term Outcomes of Cryptogenic Stroke Using the Etiological Classification System. Journal of Atherosclerosis and Thrombosis, 2023, 30, 63267.	3.7	2
121	A Nomogram for Predicting Patent Foramen Ovale-Related Stroke Recurrence. Frontiers in Neurology, 2022, 13, 903789.	3.5	3
122	Neues in der Prävention des Schlaganfalls. Gefäßmedizin Scan - Zeitschrift Für Angiologie Gefäßchirurgie Diagnostische Und Interventionelle Radiologie, 2022, 9, 145-159.	0.0	0
123	Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials. Canadian Journal of Cardiology, 2023, 39, 187-197.	3.8	1
124	Prevalence of Symptomatic Nonstenotic Carotid Disease Using Simultaneous Non-Contrast Angiography and Intraplaque Hemorrhage Imaging for MR Screen Protocol. Diagnostics, 2022, 12, 2321.	4.9	1
125	Patent Foramen Ovale: Diagnostic Evaluation and the Role of Device Closure. Clinical Medicine, 2022, 22, 441-448.	3.2	15
126	Impact of D-Dimer for Pathologic Differentiation on Transesophageal Echocardiography in Embolic Stroke of Undetermined Source: A Single-Center Experience. BMC Neurology, 2022, 22, 1-11.	2.8	3

#	Article	IF	Citations
127	Patent Foramen Ovale as the Cause of Recurrent Embolic Strokes. Case Report. Terapevticheskii Arkhiv, 2022, 94, 1109-1114.	0.9	6
128	Embolic Stroke of Undetermined Source: Current Perspectives on Diagnosis, Investigations, and Management. Canadian Journal of Cardiology, 2023, 39, 172-186.	3.8	5
129	Криптогенный инсульт. Часть 3: предсердная кардиопатия и скрытая фибрилляция предсердий. Meditsinskiy Sovet, 2022, 0, 8-18.	0.4	7
130	Potential Embolic Sources in Embolic Stroke of Undetermined Source Patients With Patent Foramen Ovale. Cerebrovascular Diseases, 2023, 52, 503-510.	2.1	5
131	A Bibliometric Analysis of Cardioembolic Stroke From 2012 to 2022. Current Problems in Cardiology, 2023, 48, 101537.	4.1	28
132	White Matter Lesions Predominantly Located in Deep White Matter Represent Embolic Etiology Rather Than Small Vessel Disease. Dementia and Neurocognitive Disorders, 2023, 22, 28-42.	3.9	1
133	Percutaneous Atrial Shunt Closure and the Risk of Recurrent Ischemic Stroke: A Register-Based, Nationwide Cohort Study. Journal of Stroke and Cerebrovascular Diseases, 2023, 32, 107084.	2.2	1
134	The Attributable Risk of Nonstenotic Cervical Carotid Plaque in Cryptogenic Embolic Stroke. , 2023, 3, e000727.		13
135	Patent Foramen Ovale-Associated Stroke Repeatedly Misdiagnosed as Cerebral Small Vessel Disease: A Case Report. Medicine (United States), 2023, 102, e32996.	2.1	3
136	Diagnosis and Management of Cardioembolic Stroke. CONTINUUM Lifelong Learning in Neurology, 2023, 29, 462.	2.1	13
137	Frequency and Size of in Situ Thrombus Within Patent Foramen Ovale. Stroke, 2023, 54, 1205-1213.	9.1	48
138	Etiologies, Mechanisms, and Risk Factors of Ischemic Stroke in a Young Asian Adult Cohort. Journal of Stroke and Cerebrovascular Diseases, 2023, 32, 107134.	2.2	11
139	Атерома дуги аорты как источник артерио-артериальной эмболии и ишемического инсульта. Vestnik Medicinskogo Instituta REAVIZ Reabilitaciâ, Vrač I Zdorov'e, 2023, 13, 31-39.	0.2	1
140	A Smart Devices Based Secondary Prevention Program for Cerebrovascular Disease Patients. Frontiers in Neurology, 2023, 14, 1176744.	3.5	9
141	CHALLENGE ESUS/CS registry. Neurosonology, 2023, 36, 3-8.	0.1	0
142	The 2022 FASEB Virtual Catalyst Conference on the Cardiac Interatrial Septum and Stroke Risk, December 7, 2022. FASEB Journal, 2023, 37, e23122.	4.2	4
143	Risk of Recurrent Ischemic Stroke in Patients With Patent Foramen Ovale: The Role of D-Dimer. Journal of Stroke and Cerebrovascular Diseases, 2023, 32, 107246.	2.2	5
144	Secondary Stroke Prevention in Patients With Patent Foramen Ovale: To Anticoagulate or Not? Fragility Index Meta-Analysis of Published Randomized Controlled Studies. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2023, 29, 256-261.	0.5	1

#	Article	IF	Citations
145	Papel do Ecocardiograma na Avaliação do Septo Interatrial e Pesquisa de Forame Oval Patente como Fonte Emboligênica. Arquivos Brasileiros De Cardiologia, 2023, 120, e20220903.	1.2	3
146	Secondary Prevention After Cardioembolic Stroke. , 2024, .		0
147	Symptomatic Extracranial Large Artery Disease. , 2024, .		0
148	Patent Foramen Ovale Closure in Special Clinical Situations: More Questions Than Answers?. Life, 2024, 14, 706.	4.3	10
149	JMIR Publications. JMIR Serious Games, 2024, 12, e53431.	5.1	8
150	Congenital Heart Disease: Types, Pathophysiology, Diagnosis, and Treatment Options. MedComm, 2024, 5, e631.	12.9	58
151	Device Closure or Antithrombotic Therapy After Cryptogenic Stroke in Elderly Patients With a High-Risk Patent Foramen Ovale. Journal of Stroke, 2024, 26, 242-251.	7.6	18
152	Symptomatic Carotid Webs and Patent Foramen Ovale: RoPE Score in Competing Stroke Etiologies. Clinical Neurology and Neurosurgery, 2024, 245, 108437.	1.9	1
153	Apixaban as a Secondary Prophylaxis Agent for Patent Foramen Ovale-Associated Stroke. Journal of Pharmacy Practice, 2025, 38, 347-350.	1.3	0
154	Measurement of Carotid Plaque Burden. , 2025, .		2
155	Anticoagulation vs Antiplatelets Across Subgroups of Embolic Stroke of Undetermined SourceA Meta-Analysis of Randomized Controlled Trials. Neurology, 2024, 103, e209949.	5.0	36
156	Treat the Patient, Not the Disease: The Embolic Stroke of Undetermined Source as an Opportunity to Optimize Cardiovascular Prevention in a Holistic Approach. European Journal of Internal Medicine, 2025, 0, 9-17.	4.2	0
157	White Matter Lesions as a Prognostic Marker of Recurrence in Cryptogenic Stroke With High-Risk Patent Foramen Ovale. Journal of Stroke and Cerebrovascular Diseases, 2024, 33, 108048.	2.2	3
158	Hotspots and Frontiers in Patent Foramen Ovale Research: A Bibliometric and Visualization Analysis From 2003 to 2023. Frontiers in Cardiovascular Medicine, 2025, 12, 1483873.	3.2	2
159	Long-Term Outcomes Following Patent Foramen Ovale Device Closure: A Single-Center Experience. Progress in Pediatric Cardiology, 2025, 77, 101824.	0.4	0
160	Clinical Research Progress on Pathogenesis and Treatment of Patent Foramen Ovale-Associated Stroke. Frontiers in Neurology, 2025, 16, 1512399.	3.5	7
161	Management of Patent Foramen Ovale-Associated Stroke: A Review of Closure vs. Medical Therapy. Ageing and Neurodegenerative Diseases, 2025, 5, N/A.	1.5	1
162	Embolic Stroke of Undetermined Source (ESUS): Exploring the Neurocardiological Axis and Its Clinical Implications. Medicina (Lithuania), 2025, 61, 1252.	3.3	6

#	Article	IF	Citations
163	Navigating the Uncertainties of Antithrombotic Therapy After Transcatheter Patent Foramen Ovale Closure: A Comprehensive Review. Catheterization and Cardiovascular Interventions, 2025, 106, 2037-2047.	2.2	4
164	Intracranial Occlusion in Cryptogenic Stroke Is Not Predictive of Recurrent Ischemic Stroke: A Propensity-Score Matched Analysis of the Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence Study. Journal of the American Heart Association, 2025, 14, e041500.	5.8	0
165	Migraine and Patent Foramen Ovale: Correlation, Coexistence, Dependence. A Narrative Review. Headache, 2026, 66, 307-321.	4.0	3
166	Understanding the Failure of Medical Therapy in PFO-Associated Stroke and the Benefits of Closure: A Narrative Review. Neurology International, 2026, 18, 11.	3.9	0
167	Role of the Transcranial Doppler Bubble Test in the Diagnostic Pathway of a Patent Foramen Ovale in Embolic Stroke of Undetermined Source. Cureus, 2026, 18, e104051.	1.3	1
168	Cryptogenic Stroke in Women: Impact of Insertable Cardiac Monitoring in the STROKEWISE Cohort Study. Europace, 2026, .	8.4	0
169	Атеро- и тромбоэмболия мозговых артерий из аорты как причина ишемического инсульта: обзор литературы. , 2026, 16, 228-237.		0
170	Patent Foramen Ovale Closure Versus Medical Therapy for Prevention of Recurrent Ischemic Events in Patients With Cryptogenic Stroke or Transient Ischemic Attack and Documented Patent Foramen Ovale: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials and Observational Studies. Frontiers in Cardiovascular Medicine, 2026, 13, 1785684.	3.2	0
171	Sekundárna prevencia ischemickej cievnej mozgovej príhody pri foramen ovale patens. Cor Et Vasa, 2026, 68, 481-485.	0.3	0
172	Anticoagulation Treatment Response Among Phenotypic ESUS Clusters: Evidence From CASPR. Annals of Clinical and Translational Neurology, 2026, .	4.3	0
173	Subclinical Atherosclerosis Burden and Patent Foramen Ovale in Young and Middle-Aged Patients With Stroke of Undetermined Etiology: A Real-Life Retrospective Cohort Study. Brain Circulation, 2026, .	4.5	0